

---

# BLOOD GROUPING REAGENT

Intended for Use in the  
United States

## Anti-Fy<sup>a</sup> (Monoclonal) (IgG)

REF

6904546  
6904547

## Anti-Fy<sup>b</sup>

## ORTHO™ Sera

MEETS FDA POTENCY REQUIREMENTS

---

### INSTRUCTIONS FOR USE

---

#### Intended Use

For *in vitro* diagnostic use only  
For use with the ID-Micro Typing System™ Anti-IgG Card  
For Indirect Antiglobulin Test

The Anti-Fy<sup>a</sup> reagent (Anti-FY1) is for the qualitative *in vitro* detection of human Fy<sup>a</sup> positive red blood cells by the indirect antiglobulin test.

The Anti-Fy<sup>b</sup> reagent (Anti-FY2) is for the qualitative *in vitro* detection of human Fy<sup>b</sup> positive red blood cells by the indirect antiglobulin test.

---

#### Summary and Explanation

Anti-Fy<sup>a</sup> and anti-Fy<sup>b</sup> (Anti-FY1 and Anti-FY2) were described in 1950 and 1951 respectively. Fy<sup>a</sup> and Fy<sup>b</sup> are a pair of alleles on the long arm of chromosome 1, giving rise to three commonly encountered phenotypes: Fy(a+b-), Fy(a+b+) and Fy(a-b+). Fy<sup>a</sup> and Fy<sup>b</sup> antigens are destroyed when the red blood cells are treated with appropriate concentrations of the proteolytic enzymes ficin, papain, and α-chymotrypsin.<sup>1</sup>

---

#### Principles of Procedure

When used by the recommended technique, the reagents will cause agglutination (clumping) of red blood cells carrying the Fy<sup>a</sup> or Fy<sup>b</sup> antigen. Lack of agglutination of the red blood cells demonstrates the absence of the Fy<sup>a</sup> or Fy<sup>b</sup> antigen.

---

#### Reagents

Anti-Fy<sup>a</sup> (Monoclonal) (IgG) and Anti-Fy<sup>b</sup> are supplied as two separate reagents.

Anti-Fy<sup>a</sup> (Monoclonal) (IgG) is supplied as one reagent.

- 1 vial containing 5 mL of human monoclonal antibodies of type IgG (cell line DG-FYA-02) containing <0.1% (w/v) sodium azide and potentiators.

Anti-Fy<sup>b</sup> is supplied as one reagent.

- 1 vial containing 5 mL of human polyclonal antibodies of type IgG containing 0.1% (w/v) sodium azide and bovine material (i.e., bovine serum albumin, fetal bovine serum).

Any bovine material used in the manufacture of these products is sourced from USDA approved facilities.

No preparation of the reagent(s) is required. Use directly from the vial. Do not dilute.

---

#### Storage Requirements

Store at 2–8 °C.

Do not freeze.

Do not use beyond expiration date. The format of the expiration date is expressed as YYYY-MM-DD (year-month-day).

May be at 18–25 °C while in use.

Replace cap when not in use.

---

#### Specimen Collection

- No special preparation of the patient/donor is required prior to specimen collection.
- Specimens should be collected by aseptic technique with an anticoagulant.
- The specimen should be tested as soon as possible after collection. If testing is delayed, the specimen should be stored at 2–8 °C.
- Do not use collection tubes that contain plasma/cell separation media.
- When using ORTHO™ Sera Anti-Fy<sup>b</sup> do not use samples collected from cord blood.
- Samples collected in EDTA should be tested within seven days from collection.
- Donor blood collected in ACD, CPD, CP2D, CPDA-1 and CP2D with AS-3 may be tested until the expiration date of the donation.
- Clotted, hemolyzed, grossly icteric or contaminated blood specimens should not be used.
- Grossly lipemic samples containing particulates that clog the gel, as indicated by diffuse blotches of red blood cells in the microtube, may be clarified by centrifugation or filtration and retested.

- Specimens should not be exposed to extreme heat.

## Precautions

Do not use if turbid.

Do not dilute.

Do not freeze.

Do not use beyond the expiration date.

The Anti-Fy<sup>a</sup> reagent contains < 0.1% (w/v) sodium azide.

The Anti-Fy<sup>b</sup> reagent contains 0.1% (w/v) sodium azide.

Handle and dispose of reagents as potentially infectious, in accordance with local, state, and national laws.

This reagent is for *in vitro* diagnostic use only.

**CAUTION:** Sodium azide may be toxic if ingested and may react with lead and copper plumbing to form explosive compounds. If discarded into sink, flush with a large volume of water to prevent azide buildup.

**CAUTION:** Source material from which this product is derived was found non-reactive for HBsAg, Anti-HIV 1/2 and Anti-HCV. No known test methods can offer complete assurance that products derived from human blood will not transmit infectious disease. Appropriate care should be taken in the use and disposal of this product. Source materials may include human components and antibody producing cells that are used in the manufacture of polyclonal and monoclonal products.

## Procedure

### Materials Provided

ORTHO™ Sera Anti-Fy<sup>a</sup>

ORTHO™ Sera Anti-Fy<sup>b</sup>

### Materials Required but not Provided

- Isotonic saline
- Reagent red blood cells suitable for the control of Anti-Fy<sup>a</sup>
- Reagent red blood cells suitable for the control of Anti-Fy<sup>b</sup>
- MTS™ Anti-Human Globulin Anti-IgG Card

**NOTE:** Store cards upright at 2–25 °C.

**CAUTION:** Inspect the condition of the card before use.  
Do not use gel cards that have not been shipped in an upright position.  
Do not use cards beyond expiration date.  
Do not freeze or expose cards to excessive heat.  
Use reagents as furnished.

- Micropipettors for delivery of 25 µL and 50 µL
- Pipet tips
- Marking pen
- ORTHO™ Workstation  
or ORTHO VISION® Analyzer  
or ORTHO VISION® Max Analyzer  
or ORTHO Optix™ Reader

### Test Procedure

#### NOTE:

The reagents have been standardized for use by the technique described below.

The indirect antiglobulin test procedure listed below is for manual testing only. When using instruments (see Materials Required but not Provided), follow the procedures that are contained in the operator's manual provided by the device manufacturer.

## INSTRUCTIONS FOR USE

## Indirect Antiglobulin Test

1. Prepare an approximate 0.8% red blood cell suspension from patient or donor cells, using isotonic saline.
2. Allow the card and the reagent(s) to come to 18–25 °C before use. A clear liquid layer should appear on top of the opaque gel in each microtube.
3. Visually inspect gel cards before use.

**CAUTION:** Do not use gel cards if the gel matrix is absent or the liquid level in the microtube is at or below the top of the gel matrix.  
Do not use gel cards that show signs of drying, discoloration, bubbles, crystals, or other artifacts.  
Do not use cards if foil seals appear damaged or opened.

**NOTE:** Refer to the ID-Micro Typing System™ Interpretation Guide<sup>2</sup> for additional information related to the visual inspection of gel cards before use.

4. Label the card appropriately with a sample identifier.
5. Remove the foil seal from the MTS™ Anti-IgG Card or from the individual microtubes to be used for testing.

**CAUTION:** Do not remove card foil seal until ready to use. Foil should be removed immediately before testing or within 1 hour of testing. Once opened, the gel may begin to dry out which could affect test results (refer to Limitations of the Procedure). After removing the foil, visually inspect all gel cards to ensure that residual film does not block the opening of any microtube.
6. Add 25 µL of the reagent to the appropriate reaction chamber(s) of the opened card.

**CAUTION:** Do not touch the pipet to the side of the reaction chamber. If this occurs, change the pipet tip before proceeding to the next chamber.
7. Add 50 µL of 0.8% red blood cell suspension to the appropriate reaction chamber(s) of the card.

**CAUTION:** Do not touch the pipet to the side of the reaction chamber. If this occurs, change the pipet tip before proceeding to the next chamber.
8. Observe that the contents of the reaction chamber(s) are combined. If necessary tap gently.

**NOTE:** Assure that the reagents remain in the reaction chamber. There should be no mixing of reactants with reagents in the column prior to centrifugation.
9. Incubate at 37 °C ± 2 °C for 15 minutes.
10. Centrifuge the card at the preset conditions, as installed by the instrument manufacturer.
11. Read the front and back of the individual columns for macroscopic agglutination or hemolysis upon test completion.
12. Record the reaction strength.

## Interpretation of Results

**Negative Result** = No agglutination and no hemolysis of the red blood cells is a negative test result. A complete sedimentation of all red blood cells is present in the bottom of the microtube.

**Positive Result** = Agglutination of the red blood cells is a positive test result. Red blood cells may remain suspended on the top of the gel or are dispersed throughout the gel in varying degrees. A few red blood cells may form a button in the bottom of the microtube in some positive reactions.

**INSTRUCTIONS FOR USE**


**Reaction Grading Guide (Use in conjunction with Diagram 1)**

<b>0 Negative</b>	Unagglutinated red blood cells form a well-defined button at the bottom of the microtube.
<b>1+ Reaction</b>	Red blood cell agglutinates are observed predominantly in the lower half of the gel microtube. Unagglutinated red blood cells form a button in the bottom of the microtube.
<b>2+ Reaction</b>	Red blood cell agglutinates are dispersed throughout the length of the gel microtube. Few unagglutinated red blood cells may be observed in the bottom of the microtube.
<b>3+ Reaction</b>	The majority of red blood cell agglutinates are trapped in the upper half of the gel microtube.
<b>4+ Reaction</b>	Solid band of red blood cell agglutinates on top of the gel. A few agglutinates may filter into the gel but remain near the predominant band.
<b>Mixed Field</b>	Red blood cell agglutinates at the top of the gel or dispersed throughout the gel microtube accompanied by a button of negative red blood cells in the bottom of the microtube. See Note below.

**NOTE:** Caution must be taken in interpreting a reaction as mixed field. Additional patient history and testing will be necessary for resolution. However, not all mixed cell situations have a sufficient minor population to be detected.

**CAUTION:** Clots, particulates or other artifacts may cause some red blood cells to be entrapped at the top of the gel that may cause an anomalous result in a negative test (refer to Limitations of the Procedure, item 6.)

**Diagram 1: Examples of Reaction Grades**



**NOTE:** Refer to ID-Micro Typing System™ Interpretation Guide<sup>2</sup> for additional information.

**Stability of Reaction**

For best results, it is recommended that reactions should be read immediately following centrifugation.

**Quality Control**

Quality Control (QC) of reagents is required. Quality Control should be performed on each lot of reagent on each day of use according to standard operating procedures.

Reagent red blood cells may be used direct from the vial as control cells in ORTHO Sera tests, including 0.8% Resolve® Panel A, 0.8% Resolve® Panel B, 0.8% Resolve® Panel C (Untreated Only), 0.8% Selectogen® and 0.8% Surgiscreen®.

**Limitations of the Procedure**

1. Strict adherence to the procedures and use of recommended equipment is essential.
2. Proper incubator parameters are important to the performance of the MTS™ Anti-IgG Card. The MTS™ Incubator and ORTHO™ Workstation have been exclusively designed to provide the correct parameters for time and temperature.
3. Proper centrifuge calibration is particularly important to the performance of the MTS™ Anti-IgG Card. The MTS™ Centrifuge and ORTHO™ Workstation have been exclusively designed to provide the correct time, speed and angle.
4. The expression of certain red blood cell antigens may diminish in strength during storage, particularly in EDTA samples. Better results will be obtained with fresh samples.
5. Suppressed or weak expression of blood group antigens may give rise to false-negative reactions.
6. Anomalous results may be caused by the following:
  - Fibrin or particulate matter.

**INSTRUCTIONS FOR USE**

- Red blood cell samples from cord blood samples when using ORTHO™ Sera Anti-Fy<sup>b</sup>.
  - Red blood cells sticking to the sides of the reaction chamber.
  - Red blood cell samples from patients with Sickle Cell Disease and patients with Malignancy, where there may be a history of previous transfusion.
  - DAT positive red blood cells.
  - Do not use cards that appear damaged (i.e., break in foil seal or break, crack or bubble in the column), exhibit drying (i.e., liquid level is at or below the top of the gel matrix) or exhibit discoloration (due to bacterial contamination, which can cause false reactions).
  - Loss of fluid in the card column may cause (weak) false positive results.
  - J reactions may occasionally be observed with high red blood cell concentrations. J reactions may also be observed if during centrifugation the card is not seated properly in the holder or not allowed to spin at a 90° angle.
- NOTE:** A J reaction consists of cells forming a button at the bottom of the gel matrix or microtube when either end of the cell button goes up the side of the column. The cell button may be disrupted. A J reaction may represent a weakly positive reaction.
- False positive or false negative test results can occur from bacterial or chemical contamination of test materials, inadequate incubation time or temperature, improper centrifugation, improper storage of materials, or omission of test samples.
7. Tests with these or other anomalous results should be repeated.
  8. Erroneous results could occur if final reactions are not read upon completion of centrifugation.
  9. Mixed cell populations may be encountered as a result of, for example, transfusion, fetal maternal hemorrhage, or transplantation. Consult patient history when results of this nature are encountered before assigning an antigen type.
  10. Donor/Patient red blood cells must be diluted with isotonic saline, before adding the red blood cells to the microtube.

**Performance Characteristics**

**Comparator Study Results**

During comparator studies (data on file at Alba Bioscience Limited), blood samples were tested with ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) and ORTHO™ Sera Anti-Fy<sup>b</sup> by ID-Micro Typing System™ Column Agglutination Technology (CAT) as follows:

**Including all samples:**

Test	Positive			Negative		
	N	% Agreement*	One-Sided Exact 95% LCL (%)	N	% Agreement*	One-Sided Exact 95% LCL (%)
Anti-Fy <sup>a</sup>	738	100.0	99.6	380	97.4	95.6
Anti-Fy <sup>b</sup>	782	99.7	99.2	353	93.5	90.9

**Excluding DAT positive samples:**

Test	Positive			Negative		
	N	% Agreement*	One-Sided Exact 95% LCL (%)	N	% Agreement*	One-Sided Exact 95% LCL (%)
Anti-Fy <sup>a</sup>	738	100.0	99.6	374	98.9	97.6
Anti-Fy <sup>b</sup>	782	99.7	99.2	348	94.8	92.4

LCL: lower confidence limit

\* % Agreement between the ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal)(IgG), ORTHO™ Sera Anti-Fy<sup>b</sup> and comparator reagents only and does not indicate which reagents gave the correct results.

**Anti-Fy<sup>a</sup>**

In performance evaluation studies, 1118 samples were tested with ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) using the MTST™ Incubator and MTS™ Centrifuge. The one-sided exact 95% LCL of positive percent agreement was ≥99% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 95.6% for agglutination tests based on a comparison of interpreted results. The NPA did not meet the acceptance criteria due to 10 discrepant results (see sample classification and comments in the summary table below).

**INSTRUCTIONS FOR USE**

The discordance between the trial and the comparator reagent could be attributed in six cases to the sample itself having a positive DAT result and in two cases, where a change from the initial test outcome was noted, to a possible error with the initial comparator test result and the differences in sensitivity between the trial and comparator reagent test methods (Weisbach et al., 1999; Weisbach et al., 2006). In the remaining two cases, where the initial test result was confirmed on investigation, no definitive root cause could be determined for the discrepant results. For these remaining two cases, both samples are included in the classification 'Sickle Cell Disease and patients with Malignancy'.

Classification	Number of Discrepancies	Comment
DAT Positive	6	Reagents which use an IAT method are not recommended for testing of samples with a positive DAT.
Sickle Cell Disease and patients with Malignancy	2	Care should be taken when interpreting results, particularly where there may be a history of previous transfusion.
Possible test error	2	ORTHO™ Sera Anti-Fy <sup>a</sup> reagent and comparator reagent gave a concordant reaction on repeat testing.

**Anti-Fy<sup>b</sup>**

In performance evaluation studies, 1135 samples were tested with ORTHO™ Sera Anti-Fy<sup>b</sup> using the MTS™ Incubator and MTS™ Centrifuge. The one-sided exact 95% LCL of positive percent agreement was ≥99% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 90.9% for agglutination tests based on a comparison of interpreted results. The NPA did not meet the acceptance criteria due to 25 discrepant results (see sample classification and comments in the summary table below).

The discordance between the trial and the comparator reagent could be attributed in five cases to the sample itself having a positive DAT result, in four cases to the inability of the comparator reagent to detect the Fy<sup>x</sup> phenotype and in seven cases, where a change to the initial test outcome was noted, to a possible error with the initial comparator test result. In the remaining nine cases, where the initial test result was confirmed on investigation, no definitive root cause could be determined for the discrepant results. For these remaining nine cases, two samples are included in the classification 'Sickle Cell Disease and patients with Malignancy', six samples are from cord blood and one sample has no specific classification (see Unresolved in the summary table below).

Discrepant test results were noted with cord blood samples which could not be attributed to sample condition, therefore, please see the Limitations of the Procedure Section for further advice.

Classification	Number of Discrepancies	Comment
DAT Positive	5	Reagents which use an IAT method are not recommended for testing of samples with a positive DAT.
Weak antigen expression	4	ORTHO™ Sera Anti-Fy <sup>b</sup> reagent showed reactivity against four known examples of Fy <sup>x</sup> antigen.
Possible test error	7	ORTHO™ Sera Anti-Fy <sup>b</sup> reagent and comparator reagent gave a concordant reaction on repeat testing.
Sickle Cell Disease and patients with Malignancy	2	Care should be taken when interpreting results, particularly where there may be a history of previous transfusion.
Cord	6	ORTHO™ Sera Anti-Fy <sup>b</sup> reagent gave a positive reaction when the comparator reagent was negative.
Unresolved	1	ORTHO™ Sera Anti-Fy <sup>b</sup> reagent and comparator reagent continued to show different result following repeat testing.

Results were evaluated against comparable FDA approved products using the appropriate methods for the comparators.

Migration studies have been performed using the ORTHO™ Workstation and results were as follows:

Reagent	Number of samples tested	Concordance*	Positive Samples	
			N	Frequency (%)
Anti-Fy <sup>a</sup>	100	100.0%	60	60
Anti-Fy <sup>b</sup>	100	100.0%	77	77

\*Concordance indicates agreement between the ORTHO™ Workstation and the MTS™ Incubator/MTS™ Centrifuge only and does not indicate which systems gave the correct results.

**INSTRUCTIONS FOR USE**

Further migration studies have been performed for the ORTHO VISION® and ORTHO VISION® Max Analyzer. Comparator studies were performed using random samples and a screening test method was used to identify additional random samples of low antigen frequency. The performance of total samples is reported in the following paragraphs, as the unscreened and screened random sample totals show similar performance.

The results of the migration studies performed using the ORTHO VISION® Analyzer were as follows:

Test	Positive			Negative		
	N	% Agreement*	One-Sided Exact 95% LCL (%)	N	% Agreement*	One-Sided Exact 95% LCL (%)
Anti-Fy <sup>a</sup>	616	100.0	99.5	600	98.8	97.8
Anti-Fy <sup>b</sup>	641	100.0	99.5	629	98.9	97.9

LCL: lower confidence limit

\* Concordance indicates agreement between the ORTHO™ Workstation and the ORTHO VISION® Analyzer only and does not indicate which system gave the correct results.

**Anti-Fy<sup>a</sup>**

In these migration studies, 1216 samples were tested with ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) using the ORTHO™ Workstation and the ORTHO VISION® Analyzer. The one-sided exact 95% LCL of positive percent agreement was 99.5% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 97.8% for agglutination tests based on a comparison of interpreted results.

Classification	Number of Discrepancies	Comment
DAT Positive	7	DAT positive following investigation. Small agglutinates may be present above the cell button resulting in a false positive result when graded by the ORTHO VISION® Analyzer.

**Anti-Fy<sup>b</sup>**

In these migration studies, 1270 samples were tested with ORTHO™ Sera Anti-Fy<sup>b</sup> using the ORTHO™ Workstation and the ORTHO VISION® Analyzer. The one-sided exact 95% LCL of positive percent agreement was 99.5% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 97.9% for agglutination tests based on a comparison of interpreted results.

Classification	Number of Discrepancies	Comment
DAT Positive	6	DAT positive following investigation. Small agglutinates may be present above the cell button resulting in a false positive result when graded by the ORTHO VISION® Analyzer.
Weak antigen expression	1	ORTHO VISION® Analyzer demonstrated increased sensitivity to the weak Fy <sup>b</sup> antigen expression compared to the ORTHO™ Workstation.

The results of the migration studies performed using the ORTHO VISION® Max Analyzer were as follows:

Test	Positive			Negative		
	N	% Agreement*	One-Sided Exact 95% LCL (%)	N	% Agreement*	One-Sided Exact 95% LCL (%)
Anti-Fy <sup>a</sup>	630	100.0	99.5	618	99.7	99.0
Anti-Fy <sup>b</sup>	607	100.0	99.5	613	99.0	98.1

LCL: lower confidence limit

\*Concordance indicates agreement between the ORTHO VISION® Analyzer and the ORTHO VISION® Max Analyzer only and does not indicate which system gave the correct results.

**Anti-Fy<sup>a</sup>**

In these migration studies, 1248 samples were tested with ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) using the ORTHO VISION® Analyzer and the ORTHO VISION® Max Analyzer. The one-sided exact 95% LCL of positive percent agreement was 99.5% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 99.0% for agglutination tests based on a comparison of interpreted results.

**Anti-Fy<sup>b</sup>**

In these migration studies, 1220 samples were tested with ORTHO™ Sera Anti-Fy<sup>b</sup> using the ORTHO VISION® Analyzer and the ORTHO VISION® Max Analyzer. The one-sided exact 95% LCL of positive percent agreement was 99.5% for agglutination tests based on a comparison of interpreted results. The one-sided exact 95% LCL of negative percent agreement (NPA) was 98.1% for agglutination tests based on a comparison of interpreted results.

Classification	Number of Discrepancies	Comment
DAT positive	5	DAT positive following investigation.
Weak antigen expression	1	Sample returned variable reactivity on both analyzers. Molecular typing of the sample indicated weak expression of the Fy <sup>b</sup> antigen causing variable reactivity.

A further migration study where a matrix approach test strategy was utilized was performed using the ORTHO Optix™ Reader. Four representative ORTHO™ Sera assays were selected for testing to migrate all 13 ORTHO™ Sera with the focus on comparable intended use and design characteristics (card types (buffered gel card and Anti-IgG gel card), special reagents (Papain) and test types (DAT and IAT)).

The results of the migration study using the ORTHO Optix™ Reader were as follows:

Card Type	Test	Positive			Negative		
		N	% Agreement*	One-Sided Exact 95% LCL (%)	N	% Agreement*	One-Sided Exact 95% LCL (%)
Buffered Gel	Anti-D (DVI) and Anti-Jk <sup>a</sup>	838	100.0	99.6	415	100.0	99.1
Anti-IgG	Anti-D (IAT) and Anti-S	647	100.0	99.4	393	99.8	98.6

LCL: lower confidence limit

\*Concordance indicates agreement between the ORTHO VISION® Analyzer and the ORTHO Optix™ Reader only and does not indicate which system gave the correct results.

In these migration studies, a total of 2293 test results were generated from 861 samples using the ORTHO Optix™ Reader and the ORTHO VISION® Analyzer. These comparator studies demonstrated greater than 95% negative percent agreement (NPA) and greater than 95% positive percent agreement (PPA) at the one-sided exact 95% LCL between the ORTHO Optix™ Reader and the ORTHO VISION® Analyzer.

**Precision Study Results**

As part of the performance evaluation, precision and lot to lot studies were performed using multiple operators, days and runs to confirm repeatability and reproducibility of test results in the same run, day and with the same operator and between runs, days and operators. The study took account of variables such as days of the week, times of day and supplementary reagents used in the testing. There were no discordant results; all expected positive test outcomes generated unequivocal positive reactions and all expected negative test outcomes generated unequivocal negative reactions.

**Specific Performance Characteristics**

Prior to release, each lot of ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) and ORTHO™ Sera Anti-Fy<sup>b</sup> are tested in alignment with FDA recommendations against a panel of antigen-positive and antigen-negative red blood cells to ensure suitable reactivity.

ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) and ORTHO™ Sera Anti-Fy<sup>b</sup> Blood Grouping Reagents have been tested using the ID-Micro Typing System™ and when stored and used according to the recommended instructions for use, found to specifically agglutinate human red blood cells with the corresponding antigen.

The ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) reagent reacts with cells expressing the Fy<sup>a</sup> antigen and meets FDA potency requirements.

The ORTHO™ Sera Anti-Fy<sup>b</sup> reagent reacts with cells expressing the Fy<sup>b</sup> antigen and meets FDA potency requirements.

For additional information or technical support, contact Ortho Care™ Technical Solutions Center on 1-800-421-3311.

**Bibliography**

1. Reid, M.E., Lomas-Francis, C. and Olsson, M.L. (2012). The Blood Group Antigen Facts Book, 3rd ed. London, Academic Press.
2. ID-Micro Typing System™ Visual Reference Guide (6902201), Ortho Clinical Diagnostics.
3. Weisbach, V., Ziener, A., Zimmermann, R., Glaser, A., Zingsem, J. and Eckstein, R. (1999) 'Comparison of the performance of four microtube column agglutination systems in the detection of red cell alloantibodies', *Transfusion*, 39(10), pp. 1045-1050.
4. Weisbach, V., Kohnhauser, T., Zimmermann, R., Ringwald, J., Strasser, E., Zingsem, J. and Eckstein, R. (2006) 'Comparison of the performance of microtube column systems and solid-phase systems and the tube low-ionic-strength solution additive indirect antiglobulin test in the detection of red cell alloantibodies', *Transfusion Medicine*, 16(4), pp. 276-284.

**Glossary of Symbols**

The following symbols may have been used in the labeling of this product.

	Do Not Reuse		Contains Sufficient for "n" Tests		Fragile, Handle with Care.
	Use by or Expiration Date (Year-Month-Day)		In vitro Diagnostic Medical Device		Keep Dry
	Batch Code or Lot Number		Upper Limit of Temperature		This end up
	Serial Number		Lower Limit of Temperature		Do Not Use if Damaged
	Catalog Number or Product Code		Temperature Limitation		Cassettes/Cards
	Date of Manufacture		Consult instructions for use		CONC Concentration
	Manufacturer		Biological Risks		Der Grüne Punkt (the Green Dot). Manufacturer follows certain packaging material waste disposal management regulations.
	Authorized Representative in the European Community				

**Summary of Revisions**

Date of Revision	Version	Section	Description of Technical Changes*
2021-03-12	6.0	Materials Required but not Provided	Addition of ORTHO Optix™ Reader and removal of MTS™ Centrifuge and MTS™ Incubator
		Performance Characteristics Comparator Study Results	Addition of Performance Characteristics for ORTHO Optix™ Reader.
2020-08-26	5.0	Specimen Collection	<ul style="list-style-type: none"> <li>• Addition of CP2D with AS-3 to list of anti-coagulant/additive solutions that can be used for the collection of donor blood.</li> <li>• Removal of "NOTE" that ORTHO™ Sera Anti-Fy<sup>a</sup> (Monoclonal) (IgG) has not been validated with CP2D with AS-3 and should not be used with this anti-coagulant/additive solution.</li> </ul>
2019-07-26	4.0	Materials Required but not Provided	Addition of ORTHO VISION® Max Analyzer.

**INSTRUCTIONS FOR USE**

Date of Revision	Version	Section	Description of Technical Changes*
		Performance Characteristics Comparator Study Results	<ul style="list-style-type: none"> <li>Added statement for migration study performed on ORTHO VISION® and ORTHO VISION® Max Analyzer.</li> <li>Updated statement for migration study data for ORTHO VISION® Analyzer.</li> <li>Addition of migration study data for ORTHO VISION® Max Analyzer.</li> </ul>
2019-01-30	3.0	Specimen Collection	Removal of CP2D with AS-3 from statement: Donor blood collected in ACD, CPD, CP2D and CPDA-1 may be tested until the expiration date of the donation.
		Materials Required but not Provided	Addition of ORTHO VISION® Analyzer.
		Test Procedure	<ul style="list-style-type: none"> <li>Changed agglutination to antiglobulin in first sentence.</li> <li>Updated statement regarding using instruments.</li> </ul>
		Quality Control	Addition of statement regarding use of 0.8% red cells as a control when used directly from the vial.
		Limitations of the Procedure	Changed limitation #10 to: Donor/Patient red blood cells must be diluted with isotonic saline, before adding the red blood cells to the microtube.
		Performance Characteristics Comparator Study Results	<ul style="list-style-type: none"> <li>Changed ORTHO ID-Micro Typing System™ to ID-Micro Typing System™.</li> <li>Addition of migration study data for ORTHO VISION® Analyzer.</li> </ul>
2018-08-01	2.0	Front page	Added Intended for Use in the United States to the header and US to the footer of the document.
		Specific Performance Characteristics	Changed OCD Customer Technical Support to Ortho Care™ Technical Solutions Center.
		Bibliography	Removed 'J' from Interpretation Guide publication number.
		Glossary of Symbols	Serious Health Hazards and Caution symbols removed.
		Back page	Manufacturer's address updated. Changed from © Ortho-Clinical Diagnostics, Inc. to © Ortho Clinical Diagnostics.
2016-07-12	1.0		Initial version of Instructions for Use.

\* The change bars indicate the position of a technical amendment to the text with respect to the previous version of the document.

U.S. License No. 1807



Distributed by:

Ortho-Clinical Diagnostics, Inc.  
1001 US Highway 202  
Raritan, NJ 08869 USA

**Ortho Clinical Diagnostics**

ORTHO™ Sera Anti-Fy<sup>a</sup> is a trademark of Ortho Clinical Diagnostics.  
ORTHO™ Sera Anti-Fy<sup>b</sup> is a trademark of Ortho Clinical Diagnostics.  
© Ortho Clinical Diagnostics, 2016-2021.